

# Curriculum Vitae -Teresa Gagliano

## Personal Information

Name: Teresa Surname: Gagliano  
Date of Birth: 28<sup>th</sup> August 1979 Citizenship: Italian  
Current Position: Associate Professor in Experimental Biology (RTD-B  
BIO/13) University of Udine (Italy)  
[teresa.gagliano@uniud.it](mailto:teresa.gagliano@uniud.it)

## **Work Experience:**

From 30/04/2023-Currently

### **Associate Professor in Experimental Biology (BIO/13)**

Department of Medicine  
University of Udine, Italy

From 30/04/2020-29/04/2023

### **Tenure-Track Assistant Professor (RTD-B) in Experimental Biology (BIO/13)**

Department of Medicine  
University of Udine, Italy

From 01/01/2020-29/04/2020

### **Senior Scientist**

Institute of Experimental Immunology-Cancer Immunobiology,  
University of Zurich, Switzerland

From 15/06/2019-31/12/2020

### **Senior Research Associate**

Department of Biochemistry, School of Life Sciences, University of Sussex, United Kingdom

### **Team Leader**

From 01/01/2018-15/06/2019

Department of Biochemistry, School of Life Sciences, University of Sussex

### **Senior Postdoctoral Fellow**

2016-2017

Department of Biochemistry, School of Life Sciences, University of Sussex

### **Postdoctoral Fellow**

From 2009- 2015

Department of Medical Science, Section of Endocrinology, University of Ferrara

### **Visiting Researcher**

Professor Paolo Pinton Lab- University of Ferrara

September 2014-December 2015, Ferrara, Italy

**Visiting Researcher**

Professor Chris McCabe Group- Centre for Endocrinology, Diabetes and Metabolism  
August 2013 – November 2013 Birmingham, United Kingdom

**Visiting Researcher**

Centro Nacional de investigaciones Oncologicas  
C/ Melchor Fernández Almagro, 3, E-28029 Madrid  
From 27/03/2011 to 30/04/2011

**Postdoctoral Fellow**

Department of Biochemistry and Molecular Biology, University of Ferrara  
From 01/01/2009 to 10/10/2009

**Postgraduate Fellow**

Department of Biochemistry and Molecular Biology, University of Ferrara  
From 01/04/2005 to 31/12/2005

**Education and Qualification**

Italian Ministry for Education, University and Research

**Associate Professorship level certification**

Endocrinology, Experimental Biology  
09/2018

University of Sussex

**Associate Fellow of the Higher Education Academy**

6/03/2017

University of Ferrara

**PhD in Biochemistry, Molecular Biology and Biotechnology**

Department of Biochemistry and Molecular Biology, University of Ferrara  
From 01/01/2006 to 31/12/2008  
Degree obtained on 27/02/2009

University of Ferrara

**MPharm**

Degree obtained AA 2007-2008

University of Ferrara

**Master of Science in Pharmaceutical Chemistry**

Degree obtained AA 2003/2004

High School Don Bosco -Villa Ranchibile (Palermo)

Degree obtained 7/7/1998

High School Educandato Statale della SS. Annunziata-Villa del Poggio Imperiale (Florence)

From 01/09/1993 to 30/06/1996

### **Academic activities**

#### 2023

Lecturer of Biology for the Nurse and Obstetricians undergraduate program, University of Udine (Italy)

Lecturer of Biology for the undergraduate program in Sport Science, University of Udine (Italy)

Lecturer of Biology for the undergraduate program in Biotechnology and Biomedical Technology, University of Udine (Italy)

#### 2022

Course convenor for the PhD students Journal Club “Cell-cell interaction”

PhD program in Biomedical Science and Biotechnology, University of Udine (Italy)

#### 2022-currently

PhD Co-supervisor, PhD candidate: Eleonora Malavasi PhD program in Biomedical Science and Biotechnology, University of Udine (Italy)

#### 2020-2022

Thesis supervisor for 6 student of BSc in Biotechnology, University of Udine (Italy)

#### 2020-Currently

Lecturer of Biology for the Nurse and Obstetricians undergraduate program, University of Udine (Italy)

Lecturer of Biology for the undergraduate program in Sport Science, University of Udine (Italy)

#### 2018-Currently

PhD co-supervisor PhD Candidate: Viviana Vella. PhD Program: Biochemistry. School of Life Sciences, University of Sussex (UK).

#### 2016-2020

PhD co-supervisor for the thesis “Targeting breast cancer via LMTK3 inhibition: from structural and functional studies to the discovery and preclinical testing in the LMTk3 small molecule inhibitor” PhD Candidate: Angeliki Ditsiou. PhD Program: Biochemistry. School of Life Sciences, University of Sussex (UK).

#### 2018-2020

PhD co-supervisor for the thesis “Pancreatic and broncho-pulmonary neuroendocrine neoplasms in vitro studies: a route from culture systems evaluation to approved and innovative therapeutic approaches”. PhD Candidate: Giulia Bresciani. PhD Program: Biomedical Sciences and Biotechnology.

University of Ferrara (Italy) and University of Sussex (UK)

#### 2018-2019

Co-supervising 3 PhD student

School of Life Sciences- University of Sussex

#### 2017-2018

Tutor for the module of Cell Biology

Spring teaching, Undergraduate, School of Life Sciences- University of Sussex

Co-supervising 2 PhD student and one MSc student,

Co-supervisor of 1 BSc Students

School of Life Sciences- University of Sussex

#### 2016-2017

Tutor for the module of Molecular Biology and Cell Biology

Autumn/Spring teaching, Undergraduate, School of Life Sciences- University of Sussex

Co-supervising 2 PhD student and one MSc student,

Co-supervisor of 2 BSc Students

School of Life Sciences- University of Sussex

#### 2015-2016

Thesis Supervisor of 1 MSc Students and co-supervisor of 1 PhD student  
(University of Sussex)

*Miss Kristzina Szabo (MSc)*. Thesis title: ‘INVESTIGATING THE CONSEQUENCES OF LMTK3 OVEREXPRESSION IN BREAST CANCER USING TWO-DIMENSIONAL (2D) AND THREE-DIMENSIONAL (3D) CELL CULTURE MODELS’  
(University of Sussex)

Marking: MSc- exams/theses marking

(University of Sussex)

#### 2013-2014

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

2014-2015

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

2014-2015

Expert technician for the Laboratory of Biochemistry for MS in Pharmaceutical Chemistry (University of Ferrara)

2013-2014

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

2012-2013

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

2011-2012

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

2010-2011

Thesis Supervisor: Bachelor of Science in Biotechnology (University of Ferrara)

Thesis Supervisor: Master of Science in Molecular and Cellular Biology (University of Ferrara)

Thesis Supervisor: Master of Science in Pharmacy and Pharmaceutical Chemistry (University of Ferrara)

Support education for the classes of Endocrinology (official teacher: Dr. Maria Chiara Zatelli) for the Bachelors degree in Biotechnology (University of Ferrara)

### 2008-2009

Expert technician for the Clinical Molecular Biology Laboratory in Cell and Biomolecular Sciences LS, Professor Francesco Bernardi (University of Ferrara)

Lessons for the course of Clinical Molecular Biology, Biomolecular Sciences in the setting of the Master degree in Molecular Biology, held by Professor Francesco Bernardi (University of Ferrara) 1. *Primary cultures of vascular smooth muscle cells* 2. *Microarray*

### 2007-2008

Academic tutor for the Faculty of Pharmacy for teaching: 1. General Chemistry 2. Organic Chemistry 3. Biochemistry (University of Ferrara)

Assistant to the tutoring methodology for the Faculty of Pharmacy, Director Dr. Roberta Ziosi (University of Ferrara)

Lectures during Clinical Molecular Biology Module held by Professor Francesco Bernardi (University of Ferrara)

1. EMSA
2. Microarray

### 2006-2007

Collaborator to methodological tutorial for the Faculty of Pharmacy, Director Dr. Roberta Ziosi (University of Ferrara)

### 2005-2006

Thesis Supervisor, Master of Science in Pharmaceutical Chemistry (University of Ferrara)

### **Honour**

- “ESE YOUNG INVESTIGATOR AWARD”- European Society of Endocrinology, 16<sup>th</sup> European Congress of Endocrinology ,Wroclaw, Poland 3-7 May 2014
- ENDOCRINE SOCIETY EARLY CAREER FORUM TRAVEL GRANT AWARD, Endocrine Society, San Diego CA (USA), 4-8 March, 2015
- Top Score Abstract “Human kinome siRNA screening to identify novel targets implicated in fibroblast-mediated triple negative breast cancer cells invasion. EACR CONFERENCE SERIES GOODBYE FLAT BIOLOGY: MODELS, MECHANISMS AND MICROENVIRONMENT. 2<sup>nd</sup> -5<sup>th</sup> October. Berlin, Germany 2016

### **Member of the following scientific societies**

- European Society of Endocrinology (ESE)
- Endocrine Society
- EACR
- AACR
- SIC
- AIBG

### **Editorial Activity**

Senior Associate Editor for Cancer Gene Therapy (IF 6.400)

<https://www.nature.com/cgt/editors>

Guest editor with Professor Giamas for the special issue “Tumor Microenvironment” Cancers (IF 6.575) [https://www.mdpi.com/journal/cancers/special\\_issues/TME](https://www.mdpi.com/journal/cancers/special_issues/TME)

Guest editor with Professor Giamas for the special issue "Extracellular Vesicles in Cancers" Biomedicines (IF4.757)

[https://www.mdpi.com/journal/biomedicines/special\\_issues/EV\\_cancers](https://www.mdpi.com/journal/biomedicines/special_issues/EV_cancers)

Editorial Board Member for Endocrinology (5.051)

[https://academic.oup.com/endo/pages/Editorial\\_Board](https://academic.oup.com/endo/pages/Editorial_Board)

Review Editor in [Molecular and Cellular Oncology](#) (Frontiers) (IF 4.848)

### **Reviewer for several journals including:**

- Oncogene (IF 8.756)
- Journal of Experimental & Clinical Cancer Research (IF 12.658)
- Molecular Oncology (IF 7.449)
- Cancer Communications (IF 15.283)

### **External referee for the following funding bodies:**

*Independent Reviewer for the Health Research Council of New Zealand*

*Independent Reviewer for the Israel Science Foundation*

*Independent reviewer for “Breast Cancer Now”UK*

*Independent reviewer for Italian Ministry of Research*

*Independent reviewer for “Swiss Cancer Research foundation & Swiss Cancer League”*

*Independent reviewer for “National Science Center, Poland”*

*Independent reviewer for the University of Parma*

*Independent reviewer for the University of Florence*

### **Meetings as speaker**

- European Neuroendocrine Association, 2nd Workshop Aggressive pituitary tumors, “Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker?” 2011 Munich, Germany
- Endocrine Diseases and Surgery: Technological Innovations and Mini-Invasive Treatments “New approaches to the treatment of adrenocortical carcinoma”, Ferrara-Italy, 7th December 2012

- SIE National Congress, EnGioI Symposium, “Magma inhibits staurosporine induced apoptosis by hampering Cytochrome C release and Caspase activation in rat pituitary adenoma cell lines” Padua , Italy 5<sup>th</sup>-8<sup>th</sup> June 2013
- European Congress of Endocrinology, 2014 ‘The cytotoxic effect of Sunitinib on human bronchial carcinoid cell lines and primary cultures, is counteracted by EGF and IGF-1, but not by VEGF’, 3<sup>rd</sup> -7<sup>th</sup> May 2014 Wroclaw, Poland.
- Meeting Club Surrene, “Sunitinib reduces cell viability of a human non-secreting adrenocortical carcinoma cell line by inhibiting EGFR phosphorylation” 17<sup>th</sup> -18<sup>th</sup> October 2014, Rome Italy
- ENETS - European Neuroendocrine Tumor Society 11th Annual ENETS Conference, “Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET” Barcelona, Spain, 2015
- 17<sup>th</sup> Congress of the European Society of Endocrinology, 16<sup>th</sup>-20<sup>th</sup> May 2015, Dublin Ireland. Guided poster tour (only for selected abstract)
  - o Receptor tyrosine kinase expression and their role in the response to target therapy in bronchopulmonary NET
  - o EGFR as potential new molecular target in the medical treatment of adrenocortical cancer
  - o TIM16 inhibition enhances sensitivity to paclitaxel and decreases calcitonin secretion by reducing mitochondrial membrane potential in a human medullary thyroid carcinoma cell line
- Italian Society of Endocrinology National Congress “TIM 16 inhibition enhances sensitivity to Doxorubicin in Human Breast Cancer Cells” 27<sup>th</sup>-30<sup>th</sup> May 2015 Taormina, Italy
- EACR conference: Goodbye to flat biology: “3D co-culture invasion screening identifies fibroblast-expressed PIK3Cδ as a novel therapeutic target for TNBC” November 2019, Berlin, German
- PI3K-Pathway August 25<sup>th</sup>-26<sup>th</sup>, 2021 | Virtual Event T “The Unexpected Function & Location of PIK3Cδ” <https://pi3k-pathways.com/whats-on/agenda/day-one/>
- AIBG, Rome 23<sup>rd</sup>/24<sup>th</sup> September 2022, “The control of the epigenetic resetting in the dysregulated proliferation of cancer cells” Teresa Gagliano, Eleonora Malavasi, Francesca Cuomo, Emanuela Kerschbamer, Christian Weichenberger Massimo Faggiani, Emiliano Dalla, Uberto Baccarani, Giovanni Terrosu, Claudio Brancolini

## **Publications**

- Manuscript in preparation

1. Malavasi E, D’Este F, Dalla E, **Gagliano T** & Brancolini C. *The role of HDAC7 in Colorectal Cancer onset and progression.*
2. **Gagliano T** , D’Este F, Dalla E, Brancolini C. *The role of HDACi in colorectal cancer treatment: investigation on the molecular mechanism using Patient-Derived organoids.*



- Peer-reviewed Articles

1. Malavasi E, Giamas G, **Gagliano T\***. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment. *Cancer Gene Ther.* 2023.
2. Brancolini C, **Gagliano T**, Minisini M. HDACs and the epigenetic plasticity of cancer cells: Target the complexity. *Pharmacol Ther.* 2022;238:108190. doi:10.1016/j.pharmthera.2022.108190
3. Giamas G, **Gagliano T\***. Cancer gene therapy 2020: highlights from a challenging year. *Cancer Gene Ther.* 2022
4. Ditsiou A, **Gagliano T**, Samuels M, Vella V, Tolia C, Giamas G. The multifaceted role of lemur tyrosine kinase 3 in health and disease. *Open Biol.* 2021 Sep;11(9):210218. doi: 10.1098/rsob.210218. Epub 2021 Sep. PMID: 34582708; PMCID: PMC8478525.
5. **Gagliano T\***, Brancolini C. Epigenetic Mechanisms beyond Tumour-Stroma Crosstalk. *Cancers (Basel).* 2021 Feb 22;13(4):914. doi:10.3390/cancers13040914. PMID: 33671588; PMCID: PMC7926949.
6. Cilibrasi C, Ditsiou A, Papakyriakou A, Mavridis G, Eravci M, Stebbing J, **Gagliano T**, Giamas G. LMTK3 inhibition affects microtubule stability. *Mol Cancer.* 2021 Mar 17;20(1):53. doi: 10.1186/s12943-021-01345-3. PMID: 33731143; PMCID: PMC7968321.
7. Brancolini C, Di Giorgio E, Formisano L, **Gagliano T**. Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9. *Life (Basel).* 2021 Jan 27;11(2):90. doi: 10.3390/life11020090. PMID: 33513699.
8. Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, Nettleship JE, Ho Lo J, Soni S, Smbatyan. G, Ntavelou P, **Gagliano T** et al. The structure-function relationship of oncogenic LMTK3. *Sci. Adv.* 6, eabc3099 (2020).
9. **Gagliano T\***, Brancolini C. Targeting histone deacetylases for combination therapies in neuroendocrine tumors. *Cancer Gene Ther.* 2020 Nov 21. doi: 10.1038/s41417-020-00260-x. Epub ahead of print. PMID: 33221822.
10. Shah K, **Gagliano T**, Garland L, O'Hanlon T, Bortolotti D, Gentili V, Rizzo R, Giamas G, Dean M. Androgen receptor signaling regulates the transcriptome of

- prostate cancer cells by modulating global alternative splicing. *Oncogene*. 2020  
doi: 10.1038/s41388-020-01429-2. PMID: 32820253
11. **Gagliano T\***<sup>1</sup>, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, Ntafis V, Huang P, Ditsiou A, Vella V, Yadav K, Bienkowska K, Bresciani G, Kang K, Li L, Carter P, Benstead-Hume G, O'Hanlon T, Dean M, Pearl FM, Lee SC, Rakha EA, Green AR, Kontoyiannis DL, Song E, Stebbing J, Giamas G. PIK3C $\delta$  expression by fibroblasts promotes triple-negative breast cancer progression. *J Clin Invest*. 2020 Mar 3:128313. doi: 10.1172/JCI128313. Online ahead of print. PMID: 32125284
  12. Bresciani G, Hofland LJ, Dogan F, Giamas G, **Gagliano T**, Zatelli MC. Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. *Front. Endocrinol*. 2019. <https://doi.org/10.3389/fendo.2019.00682>
  13. Bresciani G, Ditsiou A, Cilibrasi C, Vella V, Rea F, Schiavon M, Cavallesco NG, Giamas G, Zatelli MC, **Gagliano T\***. EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? *Endocr Connect*. 2019 8(6):680-690.
  14. Justin Stebbing, Kalpit Shah, Lei Cheng Lit, **Teresa Gagliano**, Angeliki Ditsiou, Tingting Wang, Franz Wendler, Thomas Simon<sup>4</sup>, Krisztina Sára Szabó, Timothy O'Hanlon, Michael Dean, April Camilla Roslani, Swee Hung, Cheah, Soo-Chin Lee, Georgios Giamas; LMTK3 confers chemo-resistance in breast cancer. *Oncogene*. 2018 Jun;37(23):3113-3130.
  15. Simon T, **Gagliano T**, Giamas G; Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. *Trends in Molecular Medicine* · February 2017  
DOI: 10.1016/j.molmed.2017.01.002 *Review*
  16. **Gagliano T\***, Simon, T; Giamas, Georgios; miRNA transported by exosomes: a key machinery in tumor microenvironment mediated chemoresistance *Translational Cancer Research* 5-7 S1479-S1482 2016 *Commentary*
  17. Gentilin, E; Di Pasquale, C; **Gagliano, T**; Tagliati, F; Benfìni, K; Ambrosio, MR; Bondanelli, M; degli Uberti, EC; Zatelli, MC; Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells *Molecular and cellular endocrinology* 419 252-258, 2016
  18. **Gagliano, T**; Gentilin, E; Tagliati, F; Benfìni, K; Di Pasquale, C; Feo, C; Falletta, S; Riva, E; degli Uberti, E; Zatelli, MC; Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors *Biochemical pharmacology* 98 4 639-648 2015

---

<sup>1</sup> \* Corresponding author

19. Gentilin E, Di Pasquale C, Rossi M, Tagliati F, **Gagliano T**, Rossi R, Pelizzo M, Merante Boschini I, Degli Uberti EC, Zatelli MC. Igf-I influences everolimus activity in medullary thyroid carcinoma. *Front Endocrinol (Lausanne)*. 2015 May 5;6:63. doi: 10.3389/fendo.2015.00063. eCollection 2015. PubMed PMID: 25999915; PubMed Central PMCID: PMC4419838.
20. Molè D, Gentilin E, Ibañez-Costa A, **Gagliano T**, Gahete MD, Tagliati F, Rossi R, Pelizzo MR, Pansini G, Luque RM, Castaño JP, Degli Uberti E, Zatelli MC. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. *Endocrine*. 2015 Apr 9. [Epub ahead of print] PubMed PMID: 25854304
21. Read ML, Seed RI, Modasia B, Kwan PP, Sharma N, Smith VE, Watkins RJ, Bansal S, **Gagliano T**, Stratford AL, Ismail T, Wakelam MJ, Kim DS, Ward ST, Boelaert K, Franklyn JA, Turnell AS, McCabe CJ. The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer. *Mol Carcinog*. 2014 Nov 18. doi: 10.1002/mc.22254. [Epub ahead of print] PubMed PMID: 25408419
22. Marchetti G, Girelli D, Zerbinati C, Lunghi B, Friso S, Meneghetti S, Coen M, **Gagliano T**, Guastella G, Bochaton-Piallat ML, Pizzolo F, Mascoli F, Malerba G, Bovolenta M, Ferracin M, Olivieri O, Bernardi F, Martinelli N. *An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis*. *Thromb Haemost*. 2014 Nov 6;113(3). [Epub ahead of print] PubMed PMID: 25374339.
23. **Gagliano T**, Gentilin E, Benfini K, Di Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, degli Uberti E, Zatelli MC. *Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells*. *Endocrine*. 2014 Aug 6 2014 Aug 6. [Epub ahead of print] PubMed PMID: 25096913
24. Zatelli MC#, **Gagliano T**#<sup>2</sup>, Pela' M, Bianco S, Bertolasi V, Tagliati F, Guerrini R, Degli Uberti E, Salvadori S, Trapella C. *The N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances Staurosporine cytotoxic effects likely inhibiting the protective action of Magmas towards cell apoptosis*. *J Med Chem*. 2014 Apr 24. [Epub ahead of print] PubMed PMID: 24761782.
25. Read ML, Seed RI, Fong JC, Modasia B, Ryan GA, Watkins RJ, **Gagliano T**, Smith VE, Stratford AL, Kwan PK, Sharma N, Dixon OM, Watkinson JC, Boelaert K,

---

<sup>2</sup> # These authors contributed equally to these works

- Franklyn JA, Turnell AS, McCabe CJ. *The PTTG1-Binding Factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells*. *Endocrinology*. 2014 Feb 7;en20131646. [Epub ahead of print] PubMed PMID: 24506068.
26. Gentilin E, Molè D, **Gagliano T**, Minoia M, Ambrosio MR, Uberti EC, Zatelli MC. *Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines*. *Reprod Toxicol*. 2014 Jan 30. pii: S0890-6238(14)00021-5. doi: 10.1016/j.reprotox.2014.01.008. [Epub ahead of print] PubMed PMID: 24486453.
27. Tagliati F#, **Gagliano T**#, Gentilin E, Minoia M, Molè D, Delgi Uberti EC, Zatelli MC. *Magnas overexpression inhibits staurosporine induced apoptosis in rat pituitary adenoma cell lines*. *PLoS One*. 2013 Sep 17;8(9):e75194. doi:10.1371/journal.pone.0075194. eCollection 2013. PubMed PMID: 24069394; PubMed Central PMCID: PMC3775776.
28. Coen M, Marchetti G, Palagi PM, Zerbinati C, Guastella G, **Gagliano T**, Bernardi F, Mascoli F, Bochaton-Piallat ML. *Calmodulin expression distinguishes the smooth muscle cell population of human carotid plaque*. *Am J Pathol*. 2013 Sep;183(3):996-1009. doi: 10.1016/j.ajpath.2013.06.006. Epub 2013 Jul 6. PubMed PMID: 23838429.
29. **Gagliano T**, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC. *mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids*. *Endocr Relat Cancer*. 2013 Jun 24;20(4):463-75. doi: 10.1530/ERC-13-0042. Print 2013 Aug. PubMed PMID: 23653462.
30. Molè D, Gentilin E, **Gagliano T**, Tagliati F, Bondanelli M, Pelizzo MR, Rossi M, Filieri C, Pansini G, degli Uberti EC, Zatelli MC. *Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro*. *Endocrinology*. 2012 May;153(5):2088-98. doi: 10.1210/en.2011-1988. Epub 2012 Feb 28. PubMed PMID: 22374978.
31. **Gagliano T**, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC. *Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion*. *Pituitary*. 2013 Mar;16(1):91-100. doi: 10.1007/s11102-012-0380-1. PubMed PMID: 22350942.
32. Molè D, **Gagliano T**, Gentilin E, Tagliati F, Pasquali C, Ambrosio MR, Pansini G, Degli Uberti EC, Zatelli MC. *Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors*. *Endocr Relat*

Cancer. 2011 Jul 1;18(4):439-50. doi: 10.1530/ERC-11-0055. Print 2011 Aug.  
PubMed PMID: 21606156.

33. Coen M, **Gagliano T**, Tsolaki E, Marchetti G, Marchetti E, Mascoli F. *Primary intravascular synovial sarcoma of the femoral vein in a male patient, case report*. Eur J Vasc Endovasc Surg. 2008 Aug;36(2):224-6. doi: 10.1016/j.ejvs.2008.01.028. Epub 2008 Mar 25. PubMed PMID: 18367418.

- Peer reviewed published abstracts

1. **Teresa Gagliano\***, Emanuela Kerschbamer, Eleonora Malavasi, Christian Weichenberger, Umberto Baccarani, Giovanni Terrosu, Claudio Brancolini. *Genetic and epigenetic characterization of human colorectal cancer: from tissues to organoid*. EACR Congress, Turin, Italy-June 2023
2. Eleonora Malavasi, Elisa Zamprogno, Claudio Brancolini, **Teresa Gagliano\***. *Polo-like kinase 1 (PLK1) and AURORA KINASE B modulate Histone Deacetylase 7 (HDAC7) activity in human colorectal cancer cells*. EACR Congress, Turin, Ital-2023
3. **Teresa Gagliano**, Francesca Cuomo, Massimo Faggiani, Emiliano Dalla, Francesca D'Este, Umberto Baccarani, Giovanni Terrosu, Claudio Brancolini. *Investigating the role of HDAC7 in topoisomerase I inhibitor resistance in colorectal cancer using organoids as a model*. EACR Goodbye to flat biology (virtual event) 5<sup>th</sup>-6<sup>th</sup> October 2021
4. **T Gagliano**, V Vella, K Bienkowska, A Ditsiou, G Giamas *Fibroblast-kinome silencing to identifies putative mediator of Triple-negative breast cancer (TNBC) invasion*. *Endocrine Abstracts (2018) 56 P654 | DOI: 10.1530/endoabs.56.P654*
5. A Ditsiou, **T Gagliano**, C Prodromou, J Gascon, S Mumford, D Le Grand, G Giamas. *Targeting Treatment Resistance in Breast Cancer Subtypes via LMTK3 Inhibition*. *Endocrine Abstracts (2018) 56 P651 | DOI: 10.1530/endoabs.56.P651*
6. **T Gagliano**, V Vella, K Bienkowska, A Ditsiou, G Giamas *Fibroblast-kinome siRNA screening identifies PIK3Cδ as a mediator of Triple-negative breast cancer (TNBC) invasion*. *AACR 2018*
7. **Teresa Gagliano**, Angeliki Ditsiou, Arnhild Grothey, Georgios Giamas. ER status heterogeneity in breast cancer: role in response to endocrine treatment. 19th Congress of the European Society of Endocrinology, 20th-23th May 2017, Lisbon Portugal

8. Maria Chiara Zatelli, Federico Tagliati, **Teresa Gagliano**, Claudio Trapella, Sonia Missiroli, Paolo Pinton Pinton, Cristiano Bertolucci and Ettore Ciro degli Uberti. Modulating Magma Activity to Overcome Chemoresistance. ENDO2017, 1-4 April Orlando, Florida USA
9. **Teresa Gagliano**, Eleonora Riva, Federico Tagliati, Daniele Matteotti, Valentina Brugnoli, Silvia Sambugaro, Marta Bondanelli, Erica Gentilin, Simona Falletta, Katuscia Benfini, Pasquale Carmelina Di, Remo Guerrini, Severo Salvadori, Maria Chiara Zatelli. TIM16 inhibition enhances sensitivity to paclitaxel and decreases calcitonin secretion by reducing mitochondrial membrane potential in a human medullary thyroid carcinoma cell line. *Endocrine Abstracts* (2015) 37 GP27.04 | DOI:10.1530/endoabs.37.GP.27.04
10. **Teresa Gagliano**, Federico Tagliati, Eleonora Riva, Denise Zerbini, Silvia Sambugaro, Erica Gentilin, Simona Falletta, Katuscia Benfini, Carmelina Di Pasquale, Claudio Trapella, Severo Salvadori, Ettore degli Uberti, Maria Chiara Zatelli. The sensitising action of a TIM16 inhibitor towards chemotherapeutic agents in human breast cancer cells depends on TIM16 expression. *Endocrine Abstracts* (2015) 37 EP1097 | DOI:10.1530/endoabs.37.EP1097
11. **Teresa Gagliano**, Francesco Balboni, Carmelina Di Pasquale, Erica Gentilin, Katuscia Benfini, Simona Falletta, Marta Bondanelli, Paola Franceschetti, Carlo Feo, Ettore degli Uberti, Maria Chiara Zatelli. *Endocrine Abstracts* (2015) 37 GP29.05 | DOI:10.1530/endoabs.37.GP.29.05
12. **Tersa Gagliano**, Katuscia Benfini, Erica Gentilin, Simona Falletta, Marta Bondanelli, Carmelina Di Pasquale, Eleonora Riva, Ettore degli Uberti & Maria Chiara Zatelli. Receptor tyrosine kinase expression and their role in the response to target therapy in bronchopulmonary NET. *Endocrine Abstracts* (2015) 37 GP28.04 | DOI:10.1530/endoabs.37.GP.28.04
13. **Teresa Gagliano**, Federico Tagliati, Eleonora Riva, Sambugaro Silvia, Erica Gentilin, Simona Falletta, Katuscia Benfini, Carmelina Di Pasquale, Ettore Ciro degli Uberti and Maria Chiara Zatelli. Inhibition of TIM 16 Leads to an Enhanced Sensitivity to Doxorubicin in Human Breast Cancer Cells. Pp FRI-345 *Endocrine Society's 97th Annual Meeting and Expo*, March 5–8, 2015 - San Diego
14. Zatelli Maria Chiara, Giulia Zuolo, Erica Gentilin, **Teresa Gagliano**, Federico Tagliati, and Ettore Ciro degli Uberti. Growth Hormone Modulates Chemoresistance in Human Endometrial Cancer Cell Lines. *Therapies for Cancer*, pp. MON-0336. *Endocrine Society*, 2014.

15. Zatelli Maria Chiara, Mauro Di Ruvo, Federico Tagliati, Erica Gentilin, **Teresa Gagliano**, Natalia Pellegata, Maria Rosaria Ambrosio, and Ettore Ciro degli Uberti. Acromegaly Associated with a New Deletion in CDKN1B 5'-UTR Region: Functional Molecular Characterization. Pituitary Tumors-Basic, pp. SUN-0707. Endocrine Society, 2014.
16. Zatelli Maria Chiara, Daniela Molè, Raul M. Luque, Erica Gentilin, **Teresa Gagliano**, Federico Tagliati, Alejandro Ibanez Costa et al. "The Truncated Somatostatin Receptor Variant sst5TMD4 Influences Medullary Thyroid Carcinomas Aggressivity." In Thyroid Neoplasia, pp. SUN-0558. Endocrine Society, 2014.
17. H Fan, **Teresa Gagliano**, Martin L Read, Jayne A Franklyn, Kristien Boelaert, Andrew S Turnell, Christofer J McCabe. (2014) ATR kinase function is modulated by the proto-oncogene PBF. Endocrine Abstracts (2014) 34 P191
18. **Teresa Gagliano**, Carmelina Di Pasquale, Erica Gentilin, Daniela Molè, Martina Tassinari, Mariaenrica Bellio, Ettore degli Uberti, Maria Chiara Zatelli. VEGF autocrine secretion is enhanced by EGFR activation through ERK1/2 phosphorylation in human Adrenocortical Carcinoma cell lines. Endocrine Abstracts Vol. 35 2014
19. Giulia Zuolo, Mariella Minoia, Erica Gentilin, **Teresa Gagliano**, Federico Tagliati, Maria Chiara Zatelli, Ettore degli Uberti. GH induces chemoresistance in human endometrial cancer cell lines involving ERK 1/2 and PKCdelta. Endocrine Abstracts Vol. 35 2014
20. Katuscia Benfini, **Teresa Gagliano**, Erica Gentilin, Mariella Minoia, Mole Daniela, Ettore degli Uberti, Maria Chiara Zatelli. Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids . Endocrine Abstracts Vol. 35 2014
21. Mariaenrica Bellio, Teresa Gagliano, Maria Chiara Zatelli, Ettore Degli Uberti. Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas. Endocrine Abstracts Vol. 35 2014
22. Mauro Di Ruvo, Federico Tagliati, Erica Gentilin, **Teresa Gagliano**, Natalia Pellegata, Katuscia Benfini, Ettore degli Uberti, Maria Chiara Zatelli. Functional characterization of a new deletion in CDKN1B 5'-UTR region. Endocrine Abstracts Vol. 35 2014
23. **Teresa Gagliano**, Mariaenrica Bellio, Erica Gentilin, Daniela Mole, Federico Tagliati, Marco Schiavon, Narciso Giorgio Cavallisco, Fiorella Calabrese, Maria Rosaria Ambrosio, Federico Rea, Ettore degli Uberti, Maria Chiara Zatelli (2013). mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocrine Abstracts.

24. **Teresa Gagliano**, Daniela Mole, Erica Gentilin, Mariaenrica Bellio, Uberti Ettore degli, Maria Chiara Zatelli (2013). Activation of EGFR promotes ACC cell proliferation by inducing VEGF autocrine secretion. *Endocrine Abstracts*.
25. Daniela Molè, Erica Gentilin, **Teresa Gagliano**, Federico Tagliati, degli Uberti Ettore, Maria Chiara Zatelli (2013). Involvement of PKC $\beta$  and PKC $\delta$  isoforms in TSH signaling pathway in thyroid cancer cell lines. *Endocrine Abstracts*.
26. Daniela Molè, Erica Gentilin, **Teresa Gagliano**, Federico Tagliati, Maria Rosaria Ambrosio, degli Uberti Ettore, Maria Chiara Zatelli (2013). PKC $\delta$  plays an important in regulating human medullary thyroid carcinoma cell viability. *Endocrine Abstracts*.
27. **Teresa Gagliano**, Mariaenrica Bellio, Mariella Minoia, Katiuscia Benfina, degli Uberti Ettore, Maria Chiara Zatelli (2013). Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids. *Endocrine Abstracts*.
28. Mariaenrica Bellio, Cecilia Mirabassi, **Teresa Gagliano**, Ettore degli Uberti, Zatelli Maria Chiara (2013). mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line. *Endocrine Abstracts*.
29. Erica Gentilin, Federico Tagliati, **Teresa Gagliano**, Daniela Mole, Ettore degli Uberti, Maria Chiara Zatelli (2012). PRKCD Is a Target of miR-26a in ACTH Pituitary Adenoma. *Endocrine Society , USA pp.SAT-729- SAT-729 Vol.33*,
30. Coen M., Marchetti G., Zerbinati C., Guastella G., **Gagliano T.**, Bernardi F., Palagi PM., Mascoli F., Bochaton-Piallat ML. (2012). Calmodulin Is a Marker of a Distinct Smooth Muscle Cell Population Recruited by Plaque-Derived Macrophages from the Human Carotid Artery Media. Abstract from the Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions. ATVB Council, USA pp.A519- A519 Vol.32, issue 5 supplement.
31. **T. Gagliano**, R. Rossi, D. Molè, E. Gentilin, M. Minoia, F. Tagliati, E. degli Uberti, MC. Zatelli, (2012). Differential mTOR and PI3K Pathway Activation in Human Bronchial Carcinoids. *Endocrine Society , USA pp.SUN-262- SUN-262 Vol.33*.
32. **T. Gagliano**, R. Rossi, D. Molè, E. Gentilin, M. Minoia, F. Tagliati, E. degli Uberti, M.C. Zatelli (2012). Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels. *BioScientifica, USA pp.P783- P783 Vol.29*,
33. **T. Gagliano**, A.R. Robustelli, D. Molè, E. degli Uberti, M. C. Zatelli (2011). Mitotane reduces the chemoresistance phenotype in an adrenocortical carcinoma cell line pp.76- 76 Vol.34, *Endocrine Abstract*



34. Federico Tagliati, **Teresa Gagliano**, Rachele Rossi, Silvia Borsetto, Ettore degli Uberti, Maria Chiara Zatelli (2011). Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker?. pp.P1-776- P1-776 Vol.32 , Endocrine Reviews
35. Daniela Mole', **Teresa Gagliano**, Erica Gentilin, Marta Bondanelli, Federico Tagliati, Ettore degli Uberti, and Maria Chiara Zatelli (2011). IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells. pp.P2-73- P2-73 Vol.32, Endocrine Reviews
36. Mole, D., **T. Gagliano**, E. Gentilin, M. Bondanelli, F. Tagliati, E. degli Uberti, and M. C. Zatelli. "A Novel PKC beta II Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells." In NEUROENDOCRINOLOGY, vol. 94, pp. 8-8. ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND: KARGER, 2011.
37. **T Gagliano**, AR Robustelli, D Molè, E degli Uberti, MC Zatelli (2011). Mitotane reduces the chemoresistance phenotype in an adrenocortical carcinoma cell line. Endocrine Abstracts (2011) Vol 2. European Society of Endocrinology, Bristol, UK pp.80- 80

### **Patent**

Trapella C, Guerrini R, Salvadori S, Bianco S, **Gagliano T**, Tagliati F, Zatelli MC, degli Uberti E. "Magmas inhibitors to sensitize tumor cells to therapy". International application number: 14230174, USPTO 2014

### **Grant and Funding**

- AIRC- IG 2021 Reverse the silencing: Targeting the MEF2-class IIa HDACs axis in leiomyosarcomas-Senior Member of the research team.
- 2022-2024 PON Ricerca e Innovazione 2014-2020- "Istruzione e ricerca per il recupero" REACT-EU"-Asse IV-Azione Iv.5 "Dottorati su tematiche green. Assegnazione borsa di dottorato, responsabili Claudio Brancolini e Teresa Gagliano
- 2016-2019 Action Against Cancer "Synthesis and screening of compounds to be used as LMTK3 inhibitors" (Fellowship)
- Travel grant award: "European Neuroendocrine Association", 2011 2nd Workshop Aggressive pituitary tumors, Munich, Germany
- Travel grant award "ENETS-European Neuroendocrine Tumor Society" 9th Annual ENETS Conference 2012 Copenhagen, Denmark
- Travel grant award: "European Society of Endocrinology, basic science", 15<sup>th</sup> Congress of the European Society of Endocrinology, Florence 2012
- Travel grant "European Society of Endocrinology" European Symposium on Hormones and Cell Regulation, 2012 Mont Sainte-Odile, Francia

- Travel grant award: “ENETS - European Neuroendocrine Tumor Society” 10th Annual ENETS Conference, Barcelona, Spain, 2013
- Young Researcher Fellowship Award-University of Ferrara 2013
- Travel grant award: “ENETS - European Neuroendocrine Tumor Society” 11th Annual ENETS Conference, Barcelona, Spain, 2014
- Travel grant award: “ENETS - European Neuroendocrine Tumor Society” 12th Annual ENETS Conference, Barcelona, Spain, 2015
- Travel grant award: “European Society of Endocrinology, basic science”, 17<sup>th</sup> Congress of the European Society of Endocrinology, 16<sup>th</sup>-20<sup>th</sup> May 2015, Dublin Ireland
- Travel grant award: “European Society of Endocrinology, basic science”, 19<sup>th</sup> Congress of the European Society of Endocrinology, 20<sup>th</sup>-23<sup>th</sup> May 2017, Lisbon Portugal
- Travel grant award: “European Society of Endocrinology, basic science”, 20<sup>th</sup> Congress of the European Society of Endocrinology, 19<sup>th</sup>-22<sup>th</sup> May 2018, Barcelona, Spain